Liver fat accumulation is associated with circulating PCSK9

M. Ruscica, Nicola Ferri, Chiara Macchi, Marica Meroni, Claudia Lanti, Chiara Ricci, Marco Angelo Maggioni, Anna Ludovica Fracanzani, Sara Badiali, Silvia Fargion, Paolo Magni, Luca Vittorio Carlo Valenti, Paola Dongiovanni

Research output: Contribution to journalArticlepeer-review


Background: Nonalcoholic fatty liver disease (NAFLD) associates with cardiovascular disease independently of classic risk factors. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) is secreted by hepatocytes and inhibits the uptake of low-density lipoproteins by targeting the receptor for degradation, and possibly lipogenesis. PCSK9 loss-of-function mutations and anti-PCKS9 drugs reduce LDL-cholesterol. Aim: To evaluate whether hepatic fat content is associated with circulating PCSK9. Materials and methods: In 201 consecutive patients biopsied for suspected nonalcoholic steatohepatitis, liver damage was quantified by NAFLD activity score, circulating PCSK9 by ELISA, and hepatic mRNA by qRT-PCR in a subset (n = 76). Results: Circulating PCSK9 was associated with steatosis grade (p = 0.0011), necroinflammation (p 

Original languageEnglish
Pages (from-to)384-391
Number of pages8
JournalAnnals of Medicine
Issue number5
Publication statusPublished - 2016


  • Lipids
  • lipoproteins/metabolism
  • lipoproteins/receptors
  • liver

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Liver fat accumulation is associated with circulating PCSK9'. Together they form a unique fingerprint.

Cite this